Drug Profile
Research programme: antibacterial therapeutics - Da Volterra
Alternative Names: DAV-121; DAV-210Latest Information Update: 29 Aug 2023
Price :
$50
*
At a glance
- Originator Da Volterra
- Class Anti-infectives; Antibacterials
- Mechanism of Action Bacteria replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Intestinal infections; Urinary tract infections
Most Recent Events
- 29 Aug 2023 Discontinued - Preclinical for Intestinal infections in France (PO)
- 29 Aug 2023 Discontinued - Preclinical for Urinary tract infections in France (PO)
- 28 Jan 2020 No recent reports of development identified for preclinical development in Intestinal-infections in France (PO)